Ortin Global Ltd

Ortin Global Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Ortin Global Ltd

₹ 16.7 0.00%
11 Mar 12:47 p.m.
ortinlabsindia.com BSE: 539287 NSE: ORTINGLOBE
About

Incorporated in 1986, Ortin Laboratories Ltd manufactures pharmaceutical formulations.[1]

Key Points

Business Overview:[1]
OLL is engaged in the manufacturing and trading of pharmaceuticals, drugs, and Intermediates and is also engaged in real estate.

Website BSE NSE - BE
  • Market Cap ₹ 13.6 Cr.
  • Current Price ₹ 16.7
  • High / Low ₹ 19.9 / 9.57
  • Stock P/E
  • Book Value ₹
  • Dividend Yield 0.00 %
  • ROCE %
  • ROE %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Promoter holding is low: 1.23%
  • Promoter holding has decreased over last 3 years: -14.4%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2011 Mar 2012 Jun 2012
19.81 19.77 15.93
17.13 20.77 13.85
Operating Profit 2.68 -1.00 2.08
OPM % 13.53% -5.06% 13.06%
0.01 0.19 0.03
Interest 0.55 0.98 1.12
Depreciation 0.34 0.39 0.33
Profit before tax 1.80 -2.18 0.66
Tax % 33.33% -11.93% 33.33%
1.20 -1.92 0.44
EPS in Rs 3.24 -1.14 0.26
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Dividend Payout %
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Stock Price CAGR
10 Years: -3%
5 Years: -12%
3 Years: -8%
1 Year: 38%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Equity Capital
Reserves
Total Liabilities
CWIP
Investments
Total Assets

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Net Cash Flow

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Debtor Days
Inventory Days
Days Payable
Cash Conversion Cycle
Working Capital Days
ROCE %

Insights

In beta
Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Number of Employees
Nos. ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Actual Production - Capsules
Million Nos. ・Standalone data
Actual Production - Injections (Vials/Ampoules/PFS)
Million Nos. ・Standalone data
Actual Production - Liquids
KL ・Standalone data
Actual Production - Tablets
Million Nos. ・Standalone data
Installed Capacity - Capsules
Million Nos. ・Standalone data
Installed Capacity - Injections (Vials/Ampoules/PFS)
Million Nos. ・Standalone data
Installed Capacity - Liquids
KL ・Standalone data
Installed Capacity - Tablets
Million Nos. ・Standalone data

Shareholding Pattern

Numbers in percentages

7 Recently
Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
21.51% 7.36% 7.37% 7.36% 1.23% 1.23% 1.23% 1.23% 1.23% 1.23% 1.23% 1.23%
0.00% 0.00% 0.00% 0.00% 0.00% 6.25% 6.25% 6.25% 6.53% 6.53% 1.68% 1.68%
78.49% 92.63% 92.64% 92.64% 98.76% 92.53% 92.52% 92.52% 92.24% 92.24% 97.08% 97.09%
No. of Shareholders 12,58512,18111,83612,31412,19211,95212,16512,09412,14412,03412,06011,834

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports